DigestRedComo funciona
Red
/
Empresas
Ta
No verificado

Takeda Pharmaceutical Company Limited

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

46 Comunicados de prensa

Ver todos los comunicados de prensa
28/03/2026
Eventos
Industria
Web y redes sociales
Telefonía
Salud
Medicina - Varios
Sanidad
Ciencia
Farmacéutica
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
02/03/2026
Industria
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
19/02/2026
Industria
Salud
Ciencia
Farmacéutica
Medicina - Varios
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
10/02/2026
Industria
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
29/01/2026
Biotecnología
Farmacéutica
Salud
Oncología
Mercado de valores
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
22/01/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
05/01/2026
Industria
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
18/12/2025
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
06/12/2025
Mercado laboral
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0
07/11/2025
Eventos
Industria
Biotecnología
Sanidad
Salud
Farmacéutica
Medicina - Varios
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Fuente
Takeda Pharmaceutical Company Limited
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0